EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

EssexBio Bolsters Commitment to Ophthalmology Innovation at APAO 2026 in Hong Kong

2026.02.10

EssexBio to Participate in APAO 2026 and Showcase Key Ophthalmology Assets

2026.01.22

EssexBio Forms Strategic Cooperation with Kenvue for Motrin®, Tylenol® and Rhinocort®

2025.12.17

Essex Bio-Technology establishes strategic collaboration with Biosparc Signs MOU with SIPIPO and Biosparc on International Innovation Accelerator

2025.11.21

Date

Title

2026-02-10

EssexBio Bolsters Commitment to Ophthalmology Innovation at APAO 2026 in Hong Kong

2026-01-22

EssexBio to Participate in APAO 2026 and Showcase Key Ophthalmology Assets

2025-12-17

EssexBio Forms Strategic Cooperation with Kenvue for Motrin®, Tylenol® and Rhinocort®

2025-11-21

Essex Bio-Technology establishes strategic collaboration with Biosparc Signs MOU with SIPIPO and Biosparc on International Innovation Accelerator

2025-08-26

Essex Bio-Technology (1061.HK) 2025 Interim Results at a glance

2025-08-26

Resilient Interim Results: Essex Bio-Technology Drives Growth and Innovation, Revenue up 5.8% to HK$876.5 Million, Profit up 3.8% to HK$ 163.4 million, 16.7% Dividend Surge, Continued Innovation Momentum in Regulatory Milestones

2025-08-13

NMPA Accepted Essex’s Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration.

2025-07-24

Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT